FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person*				2	2. Issuer Name and Ticker or Trading Symbol  Entered a Thoropoutics, Inc. [TRDA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Sethuraman Natarajan					Entrada Therapeutics, Inc. [ TRDA ]							X	Directo Officer	r (give title		10% Ow Other (s	· I	
(Last) (First) (Middle) C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022								below)	below) below)  Chief Scientific Officer				
(Street) BOSTON MA 02210						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person				
(City)	(S	tate)	(Zip)		Form filed by More th Person								e thar	i One Repor	ting			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		Code (Instr. 5)			4 and Securitie Beneficia		es Form ally (D) o Following (I) (Ir		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	unt (A) or (D)		Price	Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common Stock 03/01/				03/01/20	./2022		A		11,588	11,588 <sup>(1)</sup> A		<b>\$0</b> <sup>(1)</sup>	156,350 <sup>(2)</sup>			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			Code	ransaction of ode (Instr. Derivative			Expiration Date (Month/Day/Year) of So Undo Deriv			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	e V	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nur of	ount mber ares					
Stock Option (Right to Buy)	\$11.57	03/01/2022		A		69,525		(3)		03/01/2032	Common stock	69,	,525	\$0	69,525	5	D	

## **Explanation of Responses:**

- 1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- 2. Consists of (i) 118,836 shares of common stock, (ii) 25,926 shares of restricted common stock issued upon early exercise of stock options, and (iii) 11,588 RSUs reported in this transaction.
- 3. 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

/s/ Jared Cohen, as Attorney-in-03/03/2022 **Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.